UNSPSC 51372301: Meprodine

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1177I648L1. European Medicines Agency schedules Alphameprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05364MIG. Alphameprodine generally arises in the molecular formula C17H25NO2.

The term ALPHAMEPRODINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, no. 10 1969, list 9.) ALPHAMEPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1(C(CN(CC1)C)CC)C1CCCCC1)C(=O)CC.

UNSPSC 51372301 Meprodine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone and over-the-counter medications, along with drug deactivation and medication-management systems. Recent solicitations show purchasing of naloxone units and safe drug deactivation systems for community health programs, as well as generic multi-source pharmaceuticals and OTC products supplied through authorized wholesale channels to state and local facilities. The code captures both specialized emergency-response medications and routine pharmaceutical inventory procurement across health departments, community health agencies, and state purchasing coalitions. Issuing bodies include county health departments and state-level cooperative purchasing alliances serving multiple jurisdictions; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear in recent postings.

Recent activity spans Florida and Minnesota, with a broader multi-state footprint through MMCAP's cooperative model serving state and local government facilities including Oregon. Representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, and MMCAP's Request for Proposal (posted January 20, 2026; due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities through three authorized wholesalers. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 regarding direct-to-manufacturer prescription programs, signaling interest in alternative supply-chain models beyond traditional wholesale distribution. Vendors responding to these opportunities must meet cGMP and Drug Supply Chain Security Act compliance, maintain specified insurance coverage, and typically agree to fixed or net-price pricing structures.